FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044163045> ?p ?o ?g. }

• W2044163045 endingPage "259" @default.
• W2044163045 startingPage "243" @default.
• W2044163045 abstract "Apomorphine, the first dopamine agonist to be synthesized, has received a renewed interest in the last few years. This compound acts powerfully on D1 and D2 dopamine receptors and has the most complete pharmacological profile of all clinically available dopamine agonists. When given sub-cutaneously, apomorphine consistently reverses levodopa-resistant “off” periods in parkinsonian subjects: thus, it is used in cases with severe motor fluctuations, either by continuous infusion with a portable pump or by multiple injections. Studies based on this approach have been highly encouraging, as they have shown a significant reduction in off time and a good drug tolerability. The main side effect has been the occurrence of nodular skin lesions, especially when continuous infusions were used. At variance with other dopamine agonists, a low incidence of psychiatric morbidity has been reported with apomorphine. The few available comparative reports have shown that this compound is more potent and better tolerated than lisuride. Parenteral apomorphine has been used in Parkinson's disease (PD) to replace levodopa after surgery or to treat the malignant syndrome brought about by sudden levodopa withdrawal. Acute challenge with apomorphine has been used to test dopaminergic responsiveness in parkinsonian syndromes and in dystonia. The clinical response to apomorphine may predict the effect of a chronic therapy with levodopa in 90% of PD cases. Further studies are still necessary to evaluate the exact relationship between the acute response to apomorphine and a chronic therapy. In addition, apomorphine has been used to conduct clinical pharmacological studies in PD, for it is particularly well suited for research on the pharmacodynamics of central dopamine receptors. In summary, apomorphine appears to be an efficacious and safe drug for the treatment of advanced PD. It must still be considered under clinical evaluation as a test drug for acute challenge in PD and dystonia. Finally, in our opinion, the available data suggest apomorphine (in conjunction with domperidone) as a first-choice treatment for the neuroleptic malignant syndrome and the temporary replacement of levodopa (e.g., after gastrointestinal surgery)." @default.
• W2044163045 created "2016-06-24" @default.
• W2044163045 creator A5025874193 @default.
• W2044163045 creator A5036646441 @default.
• W2044163045 creator A5067217593 @default.
• W2044163045 date "1994-06-01" @default.
• W2044163045 modified "2023-10-04" @default.
• W2044163045 title "Clinical Usefulness of Apomorphine in Movement Disorders" @default.
• W2044163045 doi "https://doi.org/10.1097/00002826-199406000-00004" @default.
• W2044163045 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9316670" @default.
• W2044163045 hasPublicationYear "1994" @default.
• W2044163045 type Work @default.
• W2044163045 sameAs 2044163045 @default.
• W2044163045 citedByCount "71" @default.
• W2044163045 countsByYear W20441630452014 @default.
• W2044163045 countsByYear W20441630452016 @default.
• W2044163045 countsByYear W20441630452017 @default.
• W2044163045 countsByYear W20441630452018 @default.
• W2044163045 countsByYear W20441630452019 @default.
• W2044163045 countsByYear W20441630452020 @default.
• W2044163045 countsByYear W20441630452021 @default.
• W2044163045 countsByYear W20441630452022 @default.
• W2044163045 crossrefType "journal-article" @default.
• W2044163045 hasAuthorship W2044163045A5025874193 @default.
• W2044163045 hasAuthorship W2044163045A5036646441 @default.
• W2044163045 hasAuthorship W2044163045A5067217593 @default.
• W2044163045 hasConcept C120069818 @default.
• W2044163045 hasConcept C126322002 @default.
• W2044163045 hasConcept C137183658 @default.
• W2044163045 hasConcept C197934379 @default.
• W2044163045 hasConcept C2777095659 @default.
• W2044163045 hasConcept C2777525119 @default.
• W2044163045 hasConcept C2778258207 @default.
• W2044163045 hasConcept C2778375690 @default.
• W2044163045 hasConcept C2779134260 @default.
• W2044163045 hasConcept C2779734285 @default.
• W2044163045 hasConcept C2780304432 @default.
• W2044163045 hasConcept C42219234 @default.
• W2044163045 hasConcept C513476851 @default.
• W2044163045 hasConcept C71924100 @default.
• W2044163045 hasConcept C98274493 @default.
• W2044163045 hasConceptScore W2044163045C120069818 @default.
• W2044163045 hasConceptScore W2044163045C126322002 @default.
• W2044163045 hasConceptScore W2044163045C137183658 @default.
• W2044163045 hasConceptScore W2044163045C197934379 @default.
• W2044163045 hasConceptScore W2044163045C2777095659 @default.
• W2044163045 hasConceptScore W2044163045C2777525119 @default.
• W2044163045 hasConceptScore W2044163045C2778258207 @default.
• W2044163045 hasConceptScore W2044163045C2778375690 @default.
• W2044163045 hasConceptScore W2044163045C2779134260 @default.
• W2044163045 hasConceptScore W2044163045C2779734285 @default.
• W2044163045 hasConceptScore W2044163045C2780304432 @default.
• W2044163045 hasConceptScore W2044163045C42219234 @default.
• W2044163045 hasConceptScore W2044163045C513476851 @default.
• W2044163045 hasConceptScore W2044163045C71924100 @default.
• W2044163045 hasConceptScore W2044163045C98274493 @default.
• W2044163045 hasIssue "3" @default.
• W2044163045 hasLocation W20441630451 @default.
• W2044163045 hasLocation W20441630452 @default.
• W2044163045 hasOpenAccess W2044163045 @default.
• W2044163045 hasPrimaryLocation W20441630451 @default.
• W2044163045 hasRelatedWork W1983796423 @default.
• W2044163045 hasRelatedWork W2013253809 @default.
• W2044163045 hasRelatedWork W2013680192 @default.
• W2044163045 hasRelatedWork W2024440004 @default.
• W2044163045 hasRelatedWork W2030776824 @default.
• W2044163045 hasRelatedWork W203677622 @default.
• W2044163045 hasRelatedWork W2044163045 @default.
• W2044163045 hasRelatedWork W2066163795 @default.
• W2044163045 hasRelatedWork W2312905901 @default.
• W2044163045 hasRelatedWork W2411986191 @default.
• W2044163045 hasVolume "17" @default.
• W2044163045 isParatext "false" @default.
• W2044163045 isRetracted "false" @default.
• W2044163045 magId "2044163045" @default.
• W2044163045 workType "article" @default.